

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211753 A1

(51) International Patent Classification:
A61P 25/28 (2006.01) *C07K 16/18* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/027346

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
14 April 2021 (14.04.2021)

(25) Filing Language: English

(26) Publication Language: English

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(30) Priority Data:
63/010,261 15 April 2020 (15.04.2020) US
63/162,976 18 March 2021 (18.03.2021) US

(71) Applicant: **VOYAGER THERAPEUTICS, INC.**
[US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: **CARTER, Todd**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **HOU, Jinzhao**; 9 Tyler Road, Lexington, MA 02420 (US). **KURELLA, Vinodhbabu**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **CAPILI, Allan, D.**; 12 Dimick Street, Somerville, MA 02143 (US). **LIU, Wencheng**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **CHUNG, Hiu Yan**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **HOLTH, Jerrah**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US). **KAVANAGH, Dillon**; c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: **LU, Yu et al.**; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TAU BINDING COMPOUNDS

(57) Abstract: The present disclosure provides anti-tau antibodies and vectorization thereof (e.g., into AAV particles). Also provided are methods of using anti-tau antibodies and/or AAV particles for prevention, treatment, and/or diagnosis of neurological indications.

WO 2021/211753 A1